top of page

Synergo® SB-TS 101.3 

Disposable sets: LI932B, LI932B-S, CDS932B

​

Basic UDI-DI:

7290010121SYN101VJ (SB-TS 101.3 & LI932B/LI932B-S) - Device classification IIb

7290010121CDS932BPM (CDS932B) - classification IIa

​​

Intended Use

The Synergo System is intended for the treatment of intermediate risk, high-risk and very-high risk adult patients
with non-muscle invasive bladder cancer (NMIBC) by providing localized radiofrequency (RF) induced
bladder wall hyperthermia in combination with concurrent intravesical administration of mitomycin C (MMC)
or epirubicin. The device is intended for adjuvant (prophylactic) and neoadjuvant (ablative) treatment and intended
for use by trained healthcare professionals in hospital, clinic, or outpatient healthcare settings.

​​
Intended Users
The Synergo® RITE treatment should be performed by medical personnel (e.g. physician, nurse, medical
technician, etc.) who have undergone training by Medical Enterprises Group in the use of the Synergo® equipment, including practical hands-on training.

ce.gif

2797

If you experience a problem with one of our medical devices or wish to report a product complaint, please contact our team as soon as possible. To help us investigate your report promptly, include the clinic/hospital name, contact details, product name and model or catalog number, LOT or serial number, a description of the issue, the date the event occurred, and your contact information. If the event involved a patient or user, please include a brief description of the outcome, without providing personally identifiable information.

Email: info[at]synergo-medical.com or contact us by phone: +31 20 6423719 or +972 3 9244830

Our team will acknowledge your report and may contact you for additional information to support our investigation.

By contacting our team, you acknowledge that your email may be retained for quality assurance purposes. We may collect and process your personal information to respond to your inquiry, comply with legal obligations (including product safety requirements), investigate reported issues, and improve our products. Your information may be shared with regulatory authorities and affiliated entities, including those in the United States, where different data protection standards may apply.

Synergo  per il Trattamento del Tumore vescicale Non-Muscolo Invasivo
Synergo  - Therapie bei Nicht-Muskelinvasivem Blasenkrebs (Harnblasenkarzinom)
Synergo Kasa İnvaze Olmayan Mesane Kanseri (KIOMK) Tedavisi İçin Radyofrekans Kaynakli Termo-Kemoterapi Uygulamasi
Synergo RF technology |
Bladder preservation |
Bladder cancer treatment |
Radiofrequency-induced hyperthermia |
Microwave-induced hyperthermia |
Chemohyperthermia |
BCG unresponsive |
Cystectomy
علاج سينرغو (Synergo): فرط الحرارة الموضعي الناتج عن الميكروويف (التردد الراديوي) مع علاج كيميائي 
Технология SYNERGO для лечения мышечно-неинвазивного рака мочевого пузыря
Non-Muscle Invasive Bladder Cancer |
Synergo® Microwave (RF)-Induced Thermochemotherapy treatment for Bladder Cancer
site accessability logo WCAG 2.1AA
Informace pro pacienty s diagnózou neinvazivního karcinomu močového měchýře a léčbou přípravkem Synergo®
סרטן שלפוחית השתן וטיפול סינרגו
Niet-spierinvasieve blaaskanker: De Synergo® Behandeling
bottom of page